Navigation Links
EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
Date:10/7/2007

acies in tumor models and identified molecular targets.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the clinical trials for EPC2407 will not be successful, that EPC2407 will not receive regulatory approval or achieve significant commercial success, the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that w
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy stores ... opened in Memphis and Cordova ... in Springfield on September 24 and a ... open October 22.  MinuteClinic is the largest and fastest growing provider ... . The Memphis -area clinics join ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 23 Reportlinker.com announces that a new market research ... Eli Lilly & Co.: PharmaVitae Profile ... analysis examines the historical and forecast performance for Eli ... global company strategy, portfolio and pipeline analysis and assessment ...
... Sept. 23 As technologies for fat removal become ... not only reshaping the body but also recycling the ... to the most recent statistics from the American Society ... are among the two most popular invasive and non-invasive ...
Cached Medicine Technology:Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 2Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 3Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 4Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 5Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 6Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 7The New Face of Body Contouring 2
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... More than 60 new GranuFlo ... the past month to a federal multidistrict litigation ... caused by the dialysis concentrate, Bernstein Liebhard LLP ... 15th shows 2,089 cases filed in a federal ... of Massachusetts. These claims were filed on behalf ...
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ ... resolve,” said Steve Young of Ew Publishing; “I’ve had ... that is more intense.” , “It should be a ... migraines, that medical research is pointing to some relief ... , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found ...
(Date:9/21/2014)... Developers and plugin specialist of Final ... transition plugin entitled Transpack Vol. 3 from Pixel Film ... that will add a level of professionalism to any ... Film Studios. “Blurring the line between professional and armature, ... Transpack Vol. 3 returns with over 85 all new ...
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4
... to a report published in the October issue of ... , a grant-funded program tailored to provide advanced minimally ... helping address shortages of minority faculty members at US ... Diverse Surgeons Initiative (DSI) has helped 86 percent of ...
... Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) ... Radiology Imaging Network (ACRIN) and European Society of Breast ... study in the November issue of the Journal of ... BCSC is a collaborative effort to improve breast cancer ...
... Oct. 30 (HealthDay News) -- Hepatitis C patients who receive ... recurrent hepatitis than those who receive a liver from a ... for black patients who receive a liver from a white ... Hospital in Detroit looked at 165 hepatitis C patients who ...
... Kan. A little self-awareness can help people struggling ... professor of communication studies at the University of Kansas. ... flirting among dating adults, surveying more than 5,100 people ... "Knowing something about the way you communicate attraction says ...
... , SUNDAY, Oct. 31 (HealthDay News) -- Heat ... cool environments, a new study has found. University ... underwent a 10-day heat acclimation program achieved increases of ... and cool conditions. In terms of competitive cycling, this ...
... Reporter , FRIDAY, Oct. 29 -- A good marriage ... life and experience less pain, a new study suggests. ... that seems to buffer a patient,s emotional health," said ... the Johns Hopkins University School of Medicine in Baltimore. ...
Cached Medicine News:Health News:Diverse surgeons initiative effectively increases underrepresented minorities in academic surgery 2Health News:Majority of community facilities performing breast MRI exams meet ACRIN and EUSOBI technical requirements 2Health News:Self awareness can help people navigate rocky seas of relationships 2Health News:Good Marriages May Help Rheumatoid Arthritis Patients 2Health News:Good Marriages May Help Rheumatoid Arthritis Patients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: